1 published article · Updated continuously
16 trials tracked for Neurogenic Bladder: 7 in phase 3 or 4 and 2 with published results. The most-cited published study has 387 citations.
Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Cystoscopic injection of Botox into the urinary bladder significantly reduced the number of incontinence episodes per day (p=0.0087) 2. OnabotulinumtoxinA was also associated with changes in Incontinence Quality of Life Instrument (I-QOL) total summary scores 4.
Vaginal estriol administration resulted in a significant improvement in the Bladder Control Scale (BLCS) (p=0.002) and an increase in physical score on the MS Quality of Life Questionnaire 3. Gentamicin Sulfate was associated with a significant reduction in the number of urinary tract infections over time (p=<0.0001) 5, while its use also showed a trend toward improvement in Neurogenic Bladder Symptom Severity (NBSS) scores (p=<0.06) 5.
Tamsulosin hydrochloride was evaluated for detrusor leak point pressure (LPP); however, results were not statistically significant regarding the percentage of responders or the change from baseline in LPP at week 14 [6, 9]. Alfuzosin was associated with a decrease in the Society of Fetal Urology (SFU) Grade of Hydronephrosis in some participants 7.
Oxybutynin resulted in a statistically significant reduction in the average volume of urine collected per catheterization at week 6 (p=0.0054), though it did not significantly change the percentage of catheterizations without a leaking accident or the volume of urine collected during first morning awakening 1.
AI synthesis of 8 cited trials, updated Jul 10, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
